Adaptive Biotechnologies Corporation
ADPT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $93,973 | $58,879 | $52,443 | $47,459 |
| % Growth | 59.6% | 12.3% | 10.5% | – |
| Cost of Goods Sold | $18,157 | $17,999 | $16,979 | $18,045 |
| Gross Profit | $75,816 | $40,880 | $35,464 | $29,414 |
| % Margin | 80.7% | 69.4% | 67.6% | 62% |
| R&D Expenses | $23,669 | $24,134 | $24,203 | $23,192 |
| G&A Expenses | $17,959 | $17,786 | $17,399 | $18,056 |
| SG&A Expenses | $41,429 | $41,359 | $40,446 | $39,631 |
| Sales & Mktg Exp. | $23,470 | $23,573 | $23,047 | $21,575 |
| Other Operating Expenses | $428 | $423 | $419 | $428 |
| Operating Expenses | $65,526 | $65,916 | $65,068 | $63,251 |
| Operating Income | $10,290 | -$25,036 | -$29,604 | -$33,837 |
| % Margin | 10.9% | -42.5% | -56.4% | -71.3% |
| Other Income/Exp. Net | -$744 | -$557 | -$248 | $120 |
| Pre-Tax Income | $9,546 | -$25,593 | -$29,852 | -$33,717 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $9,546 | -$25,614 | -$29,852 | -$33,692 |
| % Margin | 10.2% | -43.5% | -56.9% | -71% |
| EPS | 0.06 | -0.17 | -0.2 | -0.23 |
| % Growth | 135.3% | 15% | 13% | – |
| EPS Diluted | 0.06 | -0.17 | -0.2 | -0.23 |
| Weighted Avg Shares Out | 152,432 | 152,082 | 149,195 | 147,102 |
| Weighted Avg Shares Out Dil | 163,162 | 152,082 | 149,195 | 147,102 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,226 | $2,391 | $2,679 | $3,072 |
| Interest Expense | $2,971 | $2,948 | $2,905 | $2,952 |
| Depreciation & Amortization | $4,405 | $4,502 | $3,153 | $4,448 |
| EBITDA | $16,922 | -$18,143 | -$29,604 | -$26,317 |
| % Margin | 18% | -30.8% | -56.4% | -55.5% |